IgH translocation prevalence according to nonhyperdiploid versus hyperdiploid status (Mayo patients)
. | . | . | Nonhyperdiploid MM . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Category and status of IgH . | No. patients . | Hyperdiploid . | Total . | Hypodiploid . | Pseudodiploid . | Tetraploid . | |||
| VH/CH strategy | |||||||||
| Not translocated, no. (% of row) | 36 | 22 (61) | 14 (39) | 2 (6) | 11 (31) | 1 (3) | |||
| Translocated, no. (% of row), P < .0001 | 44 | 5 (11) | 39 (89) | 7 (16) | 26 (59) | 6 (14) | |||
| t(11;14)(q13;q32) translocated (% of row), P NA | 29 | 2 (7) | 27 (93) | 9 (31) | 15 (52) | 3 (10) | |||
| Total patients, no.* | 109 | 29 | 80 | 18 | 52 | 10 | |||
. | . | . | Nonhyperdiploid MM . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Category and status of IgH . | No. patients . | Hyperdiploid . | Total . | Hypodiploid . | Pseudodiploid . | Tetraploid . | |||
| VH/CH strategy | |||||||||
| Not translocated, no. (% of row) | 36 | 22 (61) | 14 (39) | 2 (6) | 11 (31) | 1 (3) | |||
| Translocated, no. (% of row), P < .0001 | 44 | 5 (11) | 39 (89) | 7 (16) | 26 (59) | 6 (14) | |||
| t(11;14)(q13;q32) translocated (% of row), P NA | 29 | 2 (7) | 27 (93) | 9 (31) | 15 (52) | 3 (10) | |||
| Total patients, no.* | 109 | 29 | 80 | 18 | 52 | 10 | |||
Numbers are skewed toward nonhyperdiploid MM, and should not be used to calculate prevalence of ploidy category because of the inclusion of cases with t(11;14)(q13;q32) karyotype detected.
NA indicates not applicable.
Includes patients with either a positive VH/CH break-apart FISH assay or a t(11;14)(q13;q32).